MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'becton dickinson'. Sat, 03 Sep 2011 03:29:17 +0100 http://www.medworm.com/index.php?rid=3730094&cid=t_211024_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fjx_WgiVtYBc%2F The focus on the site is generally on pharmaceuticals, but every so often an interesting item about the device world catches our eye, as did a piece in The Washington Monthly about group purchasing organizations, or GPOs, and their impact on the health care system and innovation. The lengthy article covers familiar ground, but the upshot is that GPOs remain controversial - despite years of exposes and lawsuits, small companies still appear to have little chance to win contracts to sell their inventions to most hospitals. The oft-told tale of Retractable Technologies is the prime anecdote - the company’s syringe, which has been the subject of endless litigation, was developed with the help of government grants. But despite a settlement with several large device makers, including Becto... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3730094 Tue, 06 Jul 2010 20:55:25 +0100 3730094 http://www.medworm.com/index.php?rid=3552193&cid=t_211024_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2010%2F05%2Fleaders-of-discredited-financial-rating.html This is the latest in our informal series on the cross-linkages between the thinking and leadership that lead to the global financial collapse/ great recession and that current in health care.  Last month, a US Senate sub-committee held hearings on the role of the rating agencies, actually for-profit corporations that evaluated securities, including derivatives, in the collapse.  The Fundamentally Conflicted Rating AgenciesTo briefly provide some background, these agencies were hired by the firms that created these securities to evaluate them.  Because the securities were complex, they were hard for investors to evaluate.  Investors had become used to using the rating agencies' evaluations as benchmarks for the quality and riskiness of complex securities.  Many did... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=3552193 Mon, 10 May 2010 20:45:00 +0100 3552193 http://www.medworm.com/index.php?rid=3189334&cid=t_211024_134_f&fid=34841&url=http%3A%2F%2Fwww.diabetesmine.com%2F2010%2F01%2Fanother-commercial-partnership-jdrf-and-bd-join-forces-to-improve-insulin-pumping.html I know, I know, I had the same reaction: What the heck?! Just on the heels of the Juvenile Diabetes Research Foundation (JDRF)’s big artificial pancreas announcement last week that brings the non-profit into a commercial partnership with J&J, yesterday they released news of a new commercial partnership with Becton Dickinson (BD). The goal of [...] (Source: Diabetes Mine) Diabetes Mine blogs http://www.medworm.com/rss/comments.php?id=3189334 Wed, 20 Jan 2010 14:00:27 +0100 3189334 http://www.medworm.com/index.php?rid=2765979&cid=t_211024_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2009%2F09%2Flatest-version-of-argument-that-we-are.html Discussion) portion of the article was it mentioned that the authors had served as paid expert witnesses for plaintiffs’ attorneys in rofecoxib litigation. The terse disclosure statement seems at odds with JAMA’s stated policy in its Instructions for Authors that financial COI disclosure must be complete. Regardless, the information provided hardly conveyed that, as of January 2007, Krumholz had received more than $300,000 for his consulting from plaintiffs’ attorney Mark Lanier (no relationship to Mayo Clinic Proceedings Editor-in-Chief William L. Lanier, MD), which only became public in a letter to the editor of BMJ that responded to a previous article critical of Merck by Krumholz et al.Krumholz’ remuneration seems substantial until it is compared to that of another coauthor of ... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=2765979 Thu, 03 Sep 2009 21:30:00 +0100 2765979 http://www.medworm.com/index.php?rid=1945452&cid=t_211024_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F445486132%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? Amarin named Lars Ekman to its board; Critical Outcome Technologies named Michael Cloutier as ceo; Becton Dickinson hired David Elkins as cfo; Becton Dickinson promoted Vincent Forlenza to president; Biovail hired H. Christian Fibiger as senior vp and chief scientific officer; Tracon Pharmaceuticals appointed Bryan Leigh as chief medical officer; Novexel tapped Ken Coleman ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1945452 Fri, 07 Nov 2008 12:30:10 +0100 1945452